Feb. 3 at 8:23 PM
$INO VGX-3100 approval in Greater China (China + HK + Taiwan + Macau)
•
$23M upfront already paid
• ~
$20M in milestones coming
• Double-digit, tiered royalties (mid-teens+) for 10+ years
This is a first-in-class therapeutic HPV drug in a MASSIVE market!!
•
$1B sales → ~15% royalty =
$150M/yr to INO
•
$2B sales → ~16% royalty =
$320M/yr
•
$3B annual sales → 18% royalty =
$540M/year
That’s high-margin, recurring revenue with ZERO commercialization cost!
If VGX-3100 becomes standard of care in China, this deal alone is a INOVIO maker!!
